← Back to Search

Home-Based Supportive Care for Cancer

N/A
Waitlist Available
Led By Ryan Nipp, MD
Research Sponsored by Massachusetts General Hospital
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Patients must be age 18 or older
Receiving definitive treatment (i.e. neoadjuvant chemotherapy and/or chemoradiation with curative intent) for pancreatic, gastroesophageal, rectal, or head and neck cancer
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline to 6 months
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing a program of remotely monitoring patients with cancer who are receiving chemo, radiotherapy, or chemoradiotherapy, and providing them with home-based care.

Who is the study for?
This trial is for adults over 18 with certain cancers (pancreatic, gastroesophageal, rectal, head and neck) who are starting treatment. They must live within 50 miles of Massachusetts General Hospital, speak English fluently, and plan to receive care at MGH.
What is being tested?
The study is testing a home-based supportive oncology care program against usual care for cancer patients undergoing treatments like chemotherapy or radiotherapy. It involves remote monitoring and home care services.
What are the potential side effects?
Since this trial focuses on supportive care rather than direct medical treatments, side effects may not be as prominent but could include discomfort from remote monitoring devices or stress related to participation in the study.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am 18 years old or older.
Select...
I am undergoing treatment aimed at curing my cancer in the pancreas, stomach, esophagus, rectum, or head and neck.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline to 6 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline to 6 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Proportion of participants requiring a hospital admission or emergency department visit
Secondary study objectives
Change in Activities of Daily Living (ADLs)
Change in Instrumental Activities of Daily Living (IADLs)
Change in care satisfaction (FAMCARE)
+7 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Supportive Oncology Care at HomeExperimental Treatment1 Intervention
The research study procedures include: * Remote monitoring of symptoms, vitals, and body weight * Questionnaires asking about demographic information (e.g. gender, ethnicity, income) and experience with cancer (e.g. quality of life, symptoms) * Data collection from medical record
Group II: Usual CareActive Control1 Intervention
Participants assigned to the standard care arm will receive standard oncology care and attend regular clinic visits. Participants on the standard care arm will complete questionnaires from baseline up to 6 months following enrollment.

Find a Location

Who is running the clinical trial?

Medically HomeUNKNOWN
1 Previous Clinical Trials
72 Total Patients Enrolled
Massachusetts General HospitalLead Sponsor
3,006 Previous Clinical Trials
13,306,982 Total Patients Enrolled
Ryan Nipp, MDPrincipal Investigator - Massachusetts General Hospital
Massachusetts General Hospital, Massachusetts General Physicians Organization Inc
4 Previous Clinical Trials
434 Total Patients Enrolled

Media Library

Supportive Oncology Care at Home Clinical Trial Eligibility Overview. Trial Name: NCT04544046 — N/A
Pancreatic Cancer Research Study Groups: Supportive Oncology Care at Home, Usual Care
Pancreatic Cancer Clinical Trial 2023: Supportive Oncology Care at Home Highlights & Side Effects. Trial Name: NCT04544046 — N/A
Supportive Oncology Care at Home 2023 Treatment Timeline for Medical Study. Trial Name: NCT04544046 — N/A
~6 spots leftby Dec 2024